Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData, Phase III drugs for Fallopian Tube Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Avutometinib potassium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Avutometinib potassium overview

Avutometinib potassium (RG-7304, RO5126766) is under development for the treatment of solid tumors including low-grade serous ovarian cancer (LGSOC) , peritoneal cancer, gastroesophageal junction carcinoma, fallopian tube cancer, metastatic uveal melanoma, brain metastases from cutaneous melanoma, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, metastatic adenocarcinoma of the pancreas, non-small cell lung cancer, multiple myeloma, glioblastoma, recurrent glioblastoma, endometrial cancer, cervical cancer, HER2 negative breast cancer, anaplastic thyroid cancer, papillary thyroid carcinoma, follicular thyroid carcinoma and colorectal cancer. It is administered orally as a capsule. It is a new molecular entity (NME) with a structure based on a coumarin skeleton. The drug candidate acts by targeting B-Raf kinase, C-Raf kinase, mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1). It was also under development for prostate cancer, melanoma, pancreatic cancer and solid tumors in Japan.

Verastem overview

Verastem is a late-stage development biopharmaceutical company that develops and commercializes new medicines to treat cancer. The company’s pipeline products include avutometinib and defactinib combinations that treat low-grade serous ovarian cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer and melanoma, among others. Its avutometinib is an orally available small molecule rapidly accelerated fibrosarcoma/mitogen-activated protein kinase (RAF/MEK) clamp that inhibits the renal artery stenosis (RAS) sarcoma (RAS)/RAF/MEK, ERK mitogen-activated pathway kinase pathway which is involved in cell proliferation, migration, transformation and survival of tumor cells. Verastem’s defactinib is a selective focal adhesion kinase-1 (FAK) inhibitor monotherapy that targets solid tumors. The company operates through its subsidiaries in the US and Germany. Verastem is headquartered in Needham, Massachusetts, the US.

For a complete picture of Avutometinib potassium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.